← Back to search
CELLICS THERAPEUTICS INC
SAN DIEGO, CA, 92121
Unclaimed
WOSB· Self-reported in SAMMinority Owned
Subcontracting experience
2 records from government sources. Past participation is not evidence of current teaming interest.
| Role | Agency | Description | Vehicle | Obligated | Action date | Period |
|---|---|---|---|---|---|---|
| Subcontractor | Department of Health and Human Services | SEPSIS REMAINS A SIGNIFICANT MEDICAL CHALLENGE WITH NO EFFECTIVE TREATMENT AVAILABLE. THIS PROJECT IS TO DEVELOP A NOVEL HUMAN MACROPHAGE-DERIVED NANOSPONGE-BASED DRUG PRODUCT CANDIDATE, CTI-111, FOR THE TREATMENT OF SEPSIS CAUSED BY GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA. CTI-111 IS DESIGNED TO SEQUESTER AND INACTIVATE BACTERIAL CYTOLYTIC TOXINS, ENDOTOXINS, AND HOST PROINFLAMMATORY CYTOKINES. CTI-111 IS DERIVED FROM A MACROPHAGE CELL LINE AND WILL BE FURTHER TESTED FOR BROAD-SPECTRUM EFFICACY IN MURINE SEPSIS MODELS TO COLLECT ADDITIONAL PHARMACOLOGY DATA TO SUPPORT MECHANISM OF ACTION, LACK OF INTERFERENCE WITH ANTIBIOTICS, AND MINIMAL EFFECTIVE DOSE DETERMINATIONS. CELLICS WILL CONCURRENTLY DEVELOP A SCALABLE MANUFACTURING PROCESS TO CREATE CLINICAL TRIAL MATERIAL FOLLOWING COMPLETION OF A GOOD LABORATORY PRACTICE (GLP)-COMPLIANT NONCLINICAL TOXICOLOGY STUDY AND OTHER NONCLINICAL STUDIES TO SUPPORT INVESTIGATIONAL NEW DRUG APPLICATION (IND) FILING WITH THE U.S. FDA. 4500004626 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $644,577 | Jul 26, 2024 | — – — |
| Subcontractor | Department of Health and Human Services | SEPSIS REMAINS A SIGNIFICANT MEDICAL CHALLENGE WITH NO EFFECTIVE TREATMENT AVAILABLE. THIS PROJECT IS TO DEVELOP A NOVEL HUMAN MACROPHAGE-DERIVED NANOSPONGE-BASED DRUG PRODUCT CANDIDATE, CTI-111, FOR THE TREATMENT OF SEPSIS CAUSED BY GRAM-POSITIVE AND GRAM-NEGATIVE BACTERIA. CTI-111 IS DESIGNED TO SEQUESTER AND INACTIVATE BACTERIAL CYTOLYTIC TOXINS, ENDOTOXINS, AND HOST PROINFLAMMATORY CYTOKINES. CTI-111 IS DERIVED FROM A MACROPHAGE CELL LINE AND WILL BE FURTHER TESTED FOR BROAD-SPECTRUM EFFICACY IN MURINE SEPSIS MODELS TO COLLECT ADDITIONAL PHARMACOLOGY DATA TO SUPPORT MECHANISM OF ACTION, LACK OF INTERFERENCE WITH ANTIBIOTICS, AND MINIMAL EFFECTIVE DOSE DETERMINATIONS. CELLICS WILL CONCURRENTLY DEVELOP A SCALABLE MANUFACTURING PROCESS TO CREATE CLINICAL TRIAL MATERIAL FOLLOWING COMPLETION OF A GOOD LABORATORY PRACTICE (GLP)-COMPLIANT NONCLINICAL TOXICOLOGY STUDY AND OTHER NONCLINICAL STUDIES TO SUPPORT INVESTIGATIONAL NEW DRUG APPLICATION (IND) FILING WITH THE U.S. FDA. 4500004626 Parent award context Parent award agency: Department of Health and Human Services · Office of Assistant Secretary for Preparedness and Response Parent award NAICS: 541714 Parent award performance state: MA Parent award description: CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA View parent award on USAspending | — | $50,000 | Mar 14, 2023 | — – — |
Contract vehicles are shown only when present in the source record. Linked award numbers and vehicles open the authoritative record on USAspending.gov.